Format

Send to

Choose Destination
Sci Rep. 2018 Feb 2;8(1):2292. doi: 10.1038/s41598-018-20524-9.

Blocking extracellular activation of myostatin as a strategy for treating muscle wasting.

Author information

1
Scholar Rock, Inc, Cambridge, MA, USA.
2
Idexx Laboratories, Westbrook, ME, USA.
3
Oncorus, Cambridge, MA, USA.
4
Compass Therapeutics, Cambridge, MA, USA.
5
Scholar Rock, Inc, Cambridge, MA, USA. adonovan@scholarrock.com.

Abstract

Many growth factors are intimately bound to the extracellular matrix, with regulated processing and release leading to cellular stimulation. Myostatin and GDF11 are closely related members of the TGFβ family whose activation requires two proteolytic cleavages to release the growth factor from the prodomain. Specific modulation of myostatin and GDF11 activity by targeting growth factor-receptor interactions has traditionally been challenging. Here we demonstrate that a novel strategy for blocking myostatin and GDF11, inhibition of growth factor release, specifically and potently inhibits signaling both in vitro and in vivo. We developed human monoclonal antibodies that selectively bind the myostatin and GDF11 precursor forms, including a subset that inhibit myostatin proteolytic activation and prevent muscle atrophy in vivo. The most potent myostatin activation-blocking antibodies promoted robust muscle growth and resulted in significant gains in muscle performance in healthy mice. Altogether, we show that blocking the extracellular activation of growth factors is a potent method for preventing signaling, serving as proof of concept for a novel therapeutic strategy that can be applied to other members of the TGFβ family of growth factors.

PMID:
29396542
PMCID:
PMC5797207
DOI:
10.1038/s41598-018-20524-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center